Innoviva: The Royalty Decline Is Real, But The Valuation Is Too Pessimistic
Innoviva is a company that is transitioning from a pure royalty-based business to a diversified healthcare company with commercial products and strategic assets. I have rated Innoviva as a buy with a probability-weighted fair value of $35.26 and a base case value of $36.92. This represents a 68.1% upside from here. GSK royalties have been a main source of revenue and are now under pressure. But new therapeutic products have been ramping up to close the gap left by royalties.
Innoviva (INVA) Q2 Earnings and Revenues Top Estimates
Innoviva (INVA) came out with quarterly earnings of $0.59 per share, beating the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $0.77 per share a year ago.
Innoviva, Inc. (INVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Innoviva, Inc. (INVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Innoviva (INVA) Tops Q1 Earnings Estimates
Innoviva (INVA) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.25 per share a year ago.
3 Bargain-Cheap Small Caps Worth a Second Look
The price-to-earnings (P/E) ratio is a commonly used metric that provides a snapshot of a company's valuation. The average P/E ratio of stocks in the S&P 500 is around 27X.
Innoviva, Inc. (INVA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
Innoviva, Inc. (INVA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
Innoviva (INVA) Q3 Earnings and Revenues Beat Estimates
Innoviva (INVA) came out with quarterly earnings of $1.08 per share, beating the Zacks Consensus Estimate of $0.46 per share. This compares to earnings of $0.02 per share a year ago.
Strength Seen in Innoviva (INVA): Can Its 5.5% Jump Turn into More Strength?
Innoviva (INVA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Billionaire Healthcare Investor Alex Denner's Hedge Fund Has 75% of Its Assets in These 3 Stocks
If you work in the biotech industry, you might know the name Alex Denner.
Innoviva: Underappreciated Strength In Hospital Therapeutics
Innoviva's strong balance sheet and stable royalty income from GlaxoSmithKline provide a solid foundation for its shift to specialty therapeutics, presenting an asymmetric risk-reward profile. The company is transitioning from a royalty collector to an operator in specialty therapeutics, with significant growth in product sales, notably GIAPREZA and XACDURO. Key assets like Zevtera, an advanced-generation antibiotic, and a promising pipeline in infectious diseases, position Innoviva for potential market disruption and growth.
